REG - hVIVO plc - Exercise of Share Options

hVIVOAnnouncement

21/03/2019 10:35

RNS Number : 5890T
hVIVO plc
21 March 2019
 


 
HVIVO PLC
("hVIVO" or the "Company")
 
Exercise of Share Options
 
London, UK, 21 March 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, an application has been made to the London Stock Exchange for the admission of 644,600 new ordinary shares of 5.0p each (the "New Ordinary Shares") following an exercise of options by a former employee of the Company.
 
Admission to trading on AIM of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 26 March 2019.
 
Following Admission, the total number of ordinary shares with voting rights in issue will be 82,941,565, and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
 
For further information please contact:
 



hVIVO plc








Trevor Phillips (Executive Chairman)


+44 207 756 1300




Fleur Wood (EVP, Investor Relations & Communications)
 


 




Numis Securities Limited


 +44 207 260 1000




Michael Meade / Freddie Barnfield (Nominated Adviser)








James Black / Michael Burke (Corporate Broking)


















FTI Consulting








Simon Conway / Victoria Foster Mitchell


+44 203 727 1000



 
 
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOEBFLFLKXFXBBF